The microgram hypothesis: a translational dosing error in Epitalon peptide research and its implications for human aging application

Abstract

Epitalon (Ala-Glu-Asp-Gly), a synthetic tetrapeptide derived from the pineal gland, has attracted considerable attention in anti-aging research for its capacity to activate telomerase, restore circadian melatonin secretion, and extend lifespan across multiple species. The standard dosing convention in the longevity community, typically 5 to 10 mg per day administered subcutaneously, has persisted for over two decades without rigorous translational justification. This paper presents a hypothesis-generating translational re-examination of the preclinical and clinical evidence and identifies a fundamental translational error underlying current dosing practices. Through comparative potency analysis, we demonstrate that the 5 to 10 mg human dosing paradigm originates from studies conducted with Epithalamin, a crude polypeptide extract of bovine pineal glands, rather than with Epitalon itself. Primate data comparing both compounds reveal a model- and endpoint-specific potency differential of approximately 500-fold, while Drosophila models suggest a comparable, model-specific 1,000-fold differential in antioxidant efficacy. Allometric scaling of the effective murine treatment-day dose (1.0 μg per mouse, administered subcutaneously on 5 consecutive days each month) yields a per-treatment-day Human Equivalent dose of approximately 190 to 230 μg for a 70-kg individual. Furthermore, recent in vitro data demonstrate a non-monotonic concentration-response pattern in the BT474 breast cancer cell line, with peak telomere elongation at 0.2 μg/mL and declining effects at higher concentrations. Taken together, these findings support the testable translational hypothesis that Epitalon should be evaluated in the low microgram range, approximately 100 to 300 μg per treatment day, with treatment schedule and frequency to be defined in formal dose-finding studies, rather than the milligram range currently employed. The current practice may represent systematic overdosing rooted in the historical conflation of a crude extract with a purified synthetic peptide.

Keywords: Epitalon, Epithalamin, dosing error, allometric scaling, peptide bioregulator, geroprotection